420 related articles for article (PubMed ID: 25784518)
1. Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation.
Fauchier L; Marijon E; Defaye P; Piot O; Sadoul N; Perier MC; Gras D; Klug D; Algalarrondo V; Bordachar P; Deharo JC; Leclercq C; Babuty D; Boveda S;
Am J Cardiol; 2015 May; 115(10):1415-22. PubMed ID: 25784518
[TBL] [Abstract][Full Text] [Related]
2. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
3. Survival after implantable cardioverter-defibrillator implantation in the elderly.
Yung D; Birnie D; Dorian P; Healey JS; Simpson CS; Crystal E; Krahn AD; Khaykin Y; Cameron D; Chen Z; Lee DS
Circulation; 2013 Jun; 127(24):2383-92. PubMed ID: 23775193
[TBL] [Abstract][Full Text] [Related]
4. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
5. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
6. Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD).
Schaer BA; Kühne MS; Blatter D; Osswald S; Sticherling C
Heart; 2014 Mar; 100(6):487-91. PubMed ID: 24415667
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death.
Boulé S; Sémichon M; Guédon-Moreau L; Drumez É; Kouakam C; Marquié C; Brigadeau F; Kacet S; Potelle C; Escande W; Souissi Z; Lacroix D; Duhamel A; Klug D
Arch Cardiovasc Dis; 2016 Oct; 109(10):517-526. PubMed ID: 27342808
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
9. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
10. Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged ≥75 years versus those <75 years.
Brüllmann S; Dichtl W; Paoli U; Haegeli L; Schmied C; Steffel J; Brunckhorst C; Hintringer F; Seifert B; Duru F; Wolber T
Am J Cardiol; 2012 Mar; 109(5):712-7. PubMed ID: 22154315
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain.
van Rees JB; Borleffs CJ; Thijssen J; de Bie MK; van Erven L; Cannegieter SC; Bax JJ; Schalij MJ
Europace; 2012 Jan; 14(1):66-73. PubMed ID: 21920909
[TBL] [Abstract][Full Text] [Related]
12. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
[TBL] [Abstract][Full Text] [Related]
13. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
Schinkel AF
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):562-8. PubMed ID: 23673907
[TBL] [Abstract][Full Text] [Related]
15. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
[TBL] [Abstract][Full Text] [Related]
16. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
[TBL] [Abstract][Full Text] [Related]
17. Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators.
Lee DS; Hardy J; Yee R; Healey JS; Birnie D; Simpson CS; Crystal E; Mangat I; Nanthakumar K; Wang X; Krahn AD; Dorian P; Austin PC; Tu JV;
Circ Heart Fail; 2015 Sep; 8(5):927-37. PubMed ID: 26224792
[TBL] [Abstract][Full Text] [Related]
18. Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score.
Kraaier K; Scholten MF; Tijssen JG; Theuns DA; Jordaens LJ; Wilde AA; van Dessel PF
Europace; 2014 Jan; 16(1):40-6. PubMed ID: 23918791
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
[TBL] [Abstract][Full Text] [Related]
20. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
